Scalper1 News
Shares of Bind Therapeutics (BIND) were down more than 12% to 11.31 on the stock market today after the biotech said late Wednesday that it had ended its partnership with Amgen (AMGN). The partnership started in January 2013 to determine if Amgen’s cancer drugs could be enhanced by Bind’s nanomedicine technology. Bind’s nanoparticles, called Accurins, can be programmed to target payloads of drugs directly to cancerous tissues and cells. However, Scalper1 News
Scalper1 News